Dimiter S. Dimitrov, Ph.D.
Cancer and Inflammation Program
Building 567, Room 152
Frederick, MD 21702-1201
Protein interactions are important for understanding of biological function, and for prevention, diagnosis and treatment of diseases. Our research focuses on antibody-antigen and ligand-receptor interactions. We identify novel human monoclonal antibodies, characterize and improve their properties, elucidate their mechanisms of interactions, investigate antibody-mediated modulation of ligand-receptor interactions, and apply the knowledge gained to solve biomedical problems. Our major long-term goal is to develop antibody-based therapeutics including engineered antibody domains and antibody-guided nanoparticles against cancer and other diseases. Currently, we identify, engineer and characterize antibodies against components of the insulin-like growth factor (IGF) system and other cancer-related proteins, HIV, and emerging and biodefense-related microbes including Nipah and Hendra viruses, and dengue virus. We also study mechanisms of antibody elicitation and proposed a new (germline/maturation) concept with implications for development of vaccines against AIDS and other diseases.
Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov DS. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Curr Drug Discov Technol. 2014;11(1):28-40.
Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol. 2014;88(2):1125-39.
Sun JY, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, Low PS, Dimitrov DS, Sumer BD. In vivo optical imaging of folate receptor-β in head and neck squamous cell carcinoma. Laryngoscope. 2014;124(8):E312-9.
Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol. 2014;88(5):2426-41.
Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther. 2013;12(4):416-26.